RT Journal Article
T1 A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse.
A1 Prat, Aleix
A1 Lluch, Ana
A1 Turnbull, Arran K
A1 Dunbier, Anita K
A1 Calvo, Lourdes
A1 Albanell, Joan
A1 de la Haba-Rodriguez, Juan
A1 Arcusa, Angels
A1 Chacon, Jose Ignacio
A1 Sanchez-Rovira, Pedro
A1 Plazaola, Arrate
A1 Muñoz, Montserrat
A1 Pare, Laia
A1 Parker, Joel S
A1 Ribelles, Nuria
A1 Jimenez, Begoña
A1 Bin Aiderus, Abdul Aziz
A1 Caballero, Rosalia
A1 Adamo, Barbara
A1 Dowsett, Mitch
A1 Carrasco, Eva
A1 Martin, Miguel
A1 Dixon, J Michael
A1 Perou, Charles M
A1 Alba, Emilio
AB Purpose: Hormone receptor-positive (HR+) breast cancer is clinically and biologically heterogeneous, and subgroups with different prognostic and treatment sensitivities need to be identified.Experimental Design: Research-based PAM50 subtyping and expression of additional genes was performed on 63 patients with HR+/HER2- disease randomly assigned to neoadjuvant multiagent chemotherapy versus endocrine therapy in a phase II trial. The biology associated with treatment response was used to derive a PAM50-based chemoendocrine score (CES). CES's predictive ability was evaluated in 4 independent neoadjuvant data sets (n = 675) and 4 adjuvant data sets (n = 1,505). The association of CES, intrinsic biology, and PAM50 risk of relapse (ROR) was explored across 6,007 tumors.Results: Most genes associated with endocrine sensitivity were also found associated with chemotherapy resistance. In the chemotherapy test/validation data sets, CES was independently associated with pathologic complete response (pCR), even after adjusting for intrinsic subtype. pCR rates of the CES endocrine-sensitive (CES-E), uncertain (CES-U), and chemotherapy-sensitive (CES-C) groups in both data sets combined were 25%, 11%, and 2%, respectively. In the endocrine test/validation data sets, CES was independently associated with response. Compared with ROR, >90% of ROR-low and ROR-high tumors were identified as CES-E and CES-C, respectively; however, each CES group represented >25% of ROR-intermediate disease. In terms of survival outcome, CES-C was associated with poor relapse-free survival in patients with ROR-intermediate disease treated with either adjuvant endocrine therapy only or no adjuvant systemic therapy, but not in patients treated with (neo)adjuvant chemotherapy.Conclusions: CES is a genomic signature capable of estimating chemoendocrine sensitivity in HR+ breast cancer beyond intrinsic subtype and risk of relapse. Clin Cancer Res; 23(12); 3035-44. 
PB American Association for Cancer Research
YR 2016
FD 2016-11-07
LK http://hdl.handle.net/10668/10654
UL http://hdl.handle.net/10668/10654
LA en
NO Prat A, Lluch A, Turnbull AK, Dunbier AK, Calvo L, Albanell J, et al. A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse. Clin Cancer Res. 2017 Jun 15;23(12):3035-3044
DS RISalud
RD Apr 9, 2025